LTR Pharma Limited (AU:LTP) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
LTR Pharma Limited’s Director, Lee Rodne, has been granted 100,000 unlisted options at an exercise price of $2.52, set to expire in December 2028. This change reflects shareholder approval during the company’s 2024 Annual General Meeting. Such updates may influence investor perceptions and market activity around LTR Pharma’s stock.
For further insights into AU:LTP stock, check out TipRanks’ Stock Analysis page.